Geron Corp
GON
Company Profile
Business description
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Contact
919 East Hillsdale Boulevard
Suite 250
Foster CityCA94404
USAT: +1 650 473-7700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
229
Stocks News & Analysis
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
stocks
What next for Nine Entertainment after Domain payout?
The media group has excelled in controlling what it can control. Now the focus shifts to capital deployment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.70 | 18.10 | 0.20% |
| CAC 40 | 7,825.24 | 1.72 | 0.02% |
| DAX 40 | 23,698.15 | 5.50 | -0.02% |
| Dow JONES (US) | 45,834.22 | 273.78 | -0.59% |
| FTSE 100 | 9,283.29 | 14.29 | -0.15% |
| HKSE | 26,388.16 | 301.84 | 1.16% |
| NASDAQ | 22,141.10 | 98.03 | 0.44% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,227.90 | 1.25 | -0.01% |
| S&P 500 | 6,584.29 | 3.18 | -0.05% |
| S&P/ASX 200 | 8,864.90 | 22.00 | 0.25% |
| SSE Composite Index | 3,870.60 | 4.71 | -0.12% |